<DOC>
	<DOCNO>NCT02851329</DOCNO>
	<brief_summary>The investigator propose non-invasive prognostic tool TKIs resistance patient stage IV EGFR-mutant non-small cell lung cancer ( NSCLC ) compute tomography phenotypic feature , conveniently translate facilitate pre-therapy individualized management EGFR TKIs disease .</brief_summary>
	<brief_title>Therapeutic Resistance Prediction Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description>The investigator develop multi-CT-phenotypic-feature-based classifier predict TKI benefit therapeutic resistance stage IV EGFR-mutant non-small cell lung cancer ( NSCLC ) . The investigator also compare prognostic predictive efficacy single feature clinicopathological risk factor . An individualized nomogram integrate classifier three clinicopathological risk factor build clinical use . The prognostic accuracy propose model evaluate two independent validation set . Nearly 500 patient enrol clinical trial . Eligible patient diagnose NSCLC , stage IV accord TNM system classification American Joint Committee Cancer , presence activate EGFR mutation , age 20 year old , history systemic anticancer therapy advance disease . Patients underwent first-line second-line EGFR TKIs eligible inclusion . All patient capable undergoing contrast-enhanced CT , pretreatment CT strictly control two week EGFR TKIs start . Patients underwent resection local advance metastatic disease withdrawn study . Therapeutic resistance measure PFS , time initiation EGFR TKIs therapy date confirm disease progression death . PFS censor date death cause , date last follow-up visit progression-free patient . The investigator use extracted 1000 phenotypic feature region interest manually segment radiologist . The Lasso Cox regression model Nomogram use build prognosis model therapeutic resistance prediction EGFR TKIs stage IV EGFR-mutant NSCLC . The Harrell 's concordance index ( C-index ) propose nomogram use quantify discrimination performance .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Eligible patient diagnose NSCLC , stage IV accord TNM system classification American Joint Committee Cancer . Presence activate EGFR mutation . Age 20 year old , history systemic anticancer therapy advance disease . Patients underwent firstline secondline EGFR TKIs eligible inclusion . All patient capable undergoing contrastenhanced CT , pretreatment CT strictly control two week EGFR TKIs start . Based criterion , patient underwent resection local advance metastatic disease withdrawn study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IV EGFR-mutant</keyword>
	<keyword>EGFR TKIs</keyword>
	<keyword>progression-free survival</keyword>
	<keyword>prognosis</keyword>
	<keyword>compute tomography</keyword>
</DOC>